Department of Hematology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.
Hematology, Danish Cancer Institute, Copenhagen, Denmark.
Br J Cancer. 2024 Oct;131(7):1186-1194. doi: 10.1038/s41416-024-02816-2. Epub 2024 Aug 22.
Immunodeficiency is a shared feature of B cell malignancies. The risk of infections and their prognostic significance after diagnosis are well characterized, but, conversely, less is known about prediagnostic infections in these domains.
In matched case-control analyzes, using Danish nationwide registers, we assessed the rate of prediagnostic infections in chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), multiple myeloma (MM), follicular lymphoma (FL), marginal zone lymphoma (MZL), and lymphoplasmacytic lymphoma (LPL). Survival analyzes of data from clinical registers were then used to determine the effect of infections in the year preceding diagnosis on overall survival. To yield results for as many patients as possible, antimicrobial prescriptions were used as surrogates for infections.
The nationwide and clinical registers comprised 30,389 patients, accumulating 213,649 antimicrobial prescriptions, and 18,560 patients accumulating 107,268 prescriptions, respectively. The relative risk of infections was increased up to 15 years prior to diagnosis of malignancy and markedly increased in the year just prior to diagnosis. More than two antimicrobials within one year prior to diagnosis were associated with significantly shorter overall survival, independently of known prognostic factors.
Patients with B cell-derived malignancies exhibit marked immunodeficiency several years prior to diagnosis such that different disease subtypes demonstrate both overlapping and distinct trends in infection risk preceding diagnosis. Moreover, multiple infections within the year preceding diagnosis are independently associated with shorter overall survival for all the examined malignancies.
免疫缺陷是 B 细胞恶性肿瘤的共同特征。感染的风险及其在诊断后的预后意义已得到充分描述,但相反,在这些领域中,关于诊断前感染的了解较少。
在匹配的病例对照分析中,我们使用丹麦全国性登记册评估了慢性淋巴细胞白血病(CLL)、弥漫性大 B 细胞淋巴瘤(DLBCL)、多发性骨髓瘤(MM)、滤泡性淋巴瘤(FL)、边缘区淋巴瘤(MZL)和淋巴浆细胞淋巴瘤(LPL)的诊断前感染率。然后,使用临床登记册中的生存数据进行生存分析,以确定诊断前一年的感染对总生存的影响。为了尽可能获得更多患者的结果,我们使用抗生素处方作为感染的替代指标。
全国性和临床登记册共包括 30389 名患者,累积了 213649 次抗生素处方,18560 名患者累积了 107268 次处方。感染的相对风险在恶性肿瘤诊断前长达 15 年增加,并在诊断前一年显著增加。在诊断前一年内使用超过两种抗生素与总生存显著缩短相关,独立于已知的预后因素。
B 细胞来源恶性肿瘤患者在诊断前几年表现出明显的免疫缺陷,因此不同的疾病亚型在诊断前的感染风险上表现出重叠和独特的趋势。此外,诊断前一年内的多次感染与所有检查的恶性肿瘤的总生存缩短独立相关。